Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Herzuma in advanced gastric or gastroesophageal junction adenocarcinoma
NCT03588533Phase 2Unknown
- Start
- Jun 2018
- Primary completion
- Aug 2019
- Countries
- 1
01
Overview
Phase 2, open-label trial of trastuzumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma. Primary endpoint: Adverse events at 12 months. Status: unknown.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03588533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03588533.